424 Results

People

  1. Drilon
    Drilon
  2. Ladanyi
    Ladanyi
  3. Hyman
    Hyman
  4. Kris
    Kris
  5. Arcila
    Arcila
  6. Riely
    Riely
  7. Rudin
    Rudin
  8. Rekhtman
    Rekhtman
  9. Schram
    Schram
  10. Berger
    Berger

Groups

  1. Department of Medicine (424)
  2. Solid Tumor Oncology Division (424)
  3. Thoracic Oncology (424)
  4. GSK Faculty (143)
  5. Human Oncology and Pathogenesis Program (126)
  6. Early Drug Development Service (96)
  7. Sloan Kettering Institute Postdocs (70)
  8. Radiology, Department of (56)
  9. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (53)
  10. Gynecologic Medicine Service (53)
Formats
  1. Meeting Abstract (246)
  2. Journal Article (159)
  3. Review (10)
  4. Editorial (4)
  5. Book Section (2)
  6. Book Whole (1)
  7. Guidelines (1)
  8. Research Letter (1)
Groups
  1. Department of Medicine (424)
  2. Solid Tumor Oncology Division (424)
  3. Thoracic Oncology (424)
  4. GSK Faculty (143)
  5. Human Oncology and Pathogenesis Program (126)
  6. Early Drug Development Service (96)

More Groups

People
  1. Alexander Drilon (424)
  2. Marc Ladanyi (99)
  3. David Hyman (77)
  4. Mark Kris (72)
  5. Maria Arcila (65)
  6. Gregory Riely (55)

More People

Years
  1. 2022 (25)
  2. 2021 (76)
  3. 2020 (80)
  4. 2019 (75)
  5. 2018 (55)
  6. 2017 (33)

More Years

Publications
  1. Journal of Clinical Oncology (88)
  2. Annals of Oncology (63)
  3. Journal of Thoracic Oncology (56)
  4. Clinical Cancer Research (27)
  5. Cancer Research (18)
  6. Oncology Research and Treatment (16)

More Publications

Publishers
  1. American Society of Clinical Oncology (104)
  2. Elsevier Inc. (75)
  3. Oxford University Press (72)
  4. American Association for Cancer Research (58)
  5. Nature Publishing Group (20)
  6. S. Karger AG (16)

More Publishers

Results (424)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Editorial
    Editorial

    Li, M. M.; Drilon, A.; Laetsch, T. W.
    Cancer Genetics (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
    Journal Article

    Doz, F.; van Tilburg, C. M.; Geoerger, B.; Højgaard, M.; Øra, I.; Boni, V.; Capra, M.; Chisholm, J.; Chung, H. C.; DuBois, S. G.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
    Journal Article

    Chandran, S. S.; Ma, J.; Klatt, M. G.; Dündar, F.; Bandlamudi, C.; Razavi, P.; Wen, H. Y.; Weigelt, B.; Zumbo, P.; Fu, S. N.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Secretory carcinoma of the thyroid in a 49-year-old man treated with larotrectinib: Protracted clinical course of disease despite the high-grade histologic features
    Journal Article

    Saliba, M.; Mohanty, A. S.; Ho, A. L.; Drilon, A.; Dogan, S.
    Head and Neck Pathology (2022)

    Fulltext@MSK | Save
  • Hypersensitivity reactions to selpercatinib treatment with or without prior immune checkpoint inhibitor therapy in patients with NSCLC in LIBRETTO-001
    Journal Article

    McCoach, C. E.; Rolfo, C.; Drilon, A.; Lacouture, M.; Besse, B.; Goto, K.; Zhu, V. W.; Tan, D. S. W.; Farajian, S.; Potter, L. A.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Clinical utility and performance of an ultrarapid multiplex RNA-based assay for detection of ALK, ROS1, RET, and NTRK1/2/3 rearrangements and MET exon 14 skipping alterations
    Journal Article

    Chu, Y. H.; Barbee, J.; Yang, S. R.; Chang, J. C.; Liang, P.; Mullaney, K.; Chan, R.; Salazar, P.; Benayed, R.; Offin, M.; more...
    Journal of Molecular Diagnostics (2022)

    Fulltext@MSK | Save
  • An ascendant challenge: Central nervous system metastases in ALK+ lung cancers
    Editorial

    Murciano-Goroff, Y. R.; Harada, G.; Drilon, A.
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study
    Meeting Abstract

    Besse, B.; Johnson, M.; Ou, S. H. I.; Gadgeel, S.; Spira, A.; Lin, J.; Felip, E.; van der Wekken, A. J.; Calles, A.; de Miguel, M. J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib
    Meeting Abstract

    Moreno, V.; Lin, J. J.; Tan, D. S. W.; Lassen, U. N.; Leyvraz, S.; Liu, Y.; Patel, J.; Rosen, L.; Solomon, B.; Rudolph, M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Drilon, A.; Subbiah, V.; Gautschi, O.; Tomasini, P.; De Braud, F. G. M.; Solomon, B.; Tan, D. S. W.; Alonso, G.; Wolf, J.; Park, K.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save